Navamedic ASA: Amendments to loan agreements with Observe Medical ASA

Navamedic ASA: Mandatory notice of trade

Navamedic launches Eroxon[®] in Finland

Navamedic Q3 2024: Business remains strong in quarter impacted by cyclical nature of the business

Navamedic ASA: Invitation to 2024 3rd quarter presentation

Navamedic wins joint Nordic antibiotics tender